Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma

Completed

• Conditions: Embryonal Childhood Rhabdomyosarcoma; Recurrent Childhood Rhabdomyosarcoma; Alveolar Childhood Rhabdomyosarcoma; Previously Untreated Childhood Rhabdomyosarcoma; Previously Treated Childhood Rhabdomyosarcoma
• Interventions: Other: laboratory biomarker analysis

• Registration Number: NCT01626170
• Lead Sponsor: Children's Oncology Group

Brief Summary

This laboratory study is looking into mechanisms of radiation therapy resistance in samples from younger patients with rhabdomyosarcoma. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer

Detailed Description

Observational Study Model: Cohort Time Perspective: Retrospective Biospecimen Retention: Samples with DNA Biospecimen Description: Tissue Study Population Description: Primary care clinic Sampling Method: Non-probability sample

OBJECTIVES:

I. Determine the molecular response/resistance signatures with radiotherapy and standard chemoradiation treatments using the xenograft model of the Pediatric Preclinical Testing Program (PPTP).

II. Validate these novel pathways/biomarkers by their detection within clinically annotated patient tumor tissue samples and testing their associations with clinical response, local control rates, and overall survival rates.

OUTLINE: Archived tissue samples of matched primary-relapsed and non-matched primary are analyzed for genomic DNA, DNA methylation profiles, RNA sequencing, differences between alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS), gene expression profiles, target-of-rapamycin complex 1 (TORC1) and TORC2 pathway intermediates, and paired box 3 (PAX3)/forkhead box O1 (FOXO1) translocation by microarray, immunohistochemical staining, and fluorescence in situ hybridization (FISH).

Study Timeline

• Study Start: 2012-06
• Study First Submitted: 2012-06-20
• Study First Submitted QC: 2012-06-20
• Study First Posted: 2012-06-22
• Primary Completion: 2013-10
• Status Verified: 2016-07
• Last Update Submitted: 2016-07-13
• Last Update Posted: 2016-07-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Tissues requested from the Children Oncology Group (COG) sarcoma banking protocol COG-D9902

• All subtypes of rhabdomyosarcoma specimens

  • Matched primary-relapsed specimens (from same patient, separated by time):

    • Frozen tissue if available
    • Scrolls of formalin-fixed paraffin-embedded tissue (if frozen not available)
    • 10 unstained formalin-fixed paraffin-embedded thin sections

  • All other general (primary or relapsed) cases

    • 10 unstained formalin-fixed paraffin-embedded thin sections

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Correlative (laboratory biomarker analysis)	laboratory biomarker analysis	Archived tissue samples of matched primary-relapsed and non-matched primary are analyzed for genomic DNA, DNA methylation profiles, RNA sequencing, differences between alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS), gene expression profiles, target-of-rapamycin complex 1 (TORC1) and TORC2 pathway intermediates, and paired box 3 (PAX3)/forkhead box O1 (FOXO1) translocation by microarray, immunohistochemical staining, and fluorescence in situ hybridization (FISH).

Primary Outcome Measures

Name	Time	Method
Novel pathway/biomarkers detected within clinically annotated patient tumor tissue samples	Up to 1 year
Molecular response	Up to 1 year

Trial Locations

Locations (1)

Children's Oncology Group; 🇺🇸 Monrovia, California, United States